CX NEWS
STEP seeks to advance patient safety after TEVAR
Stroke is a major concern following TEVAR (thoracic endovascular aortic repair) and Charing Cross delegates heard the results from a collaborative study that pooled practice data from a number of high-volume centres in order [...]
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018
Ulf Teichgräber discusses the EffPAC trial 12-month results which were presented for the first time at CX 2018 Ulf Teichgräber, Jena, Germany
EVAS is associated with a reduction in all-cause mortality
EVAS is associated with a reduction in all-cause mortality Marc Schermerhorn, Boston, United States
Podium 1st: Lutonix AV IDE interim 24 month update
Podium 1st: Lutonix AV IDE interim 24 month update Kate Steiner, Stevenage, United Kingdom
“Promising” initial results for sirolimus-eluting bioresorbable scaffold in DESappear trial
Andrew Holden The sirolimus-eluting bioresorbable peripheral scaffold system (Prava; Elixir Medical) is designed to treat stenoses and occlusion in the superficial femoral artery. Prava was first implanted in October 2016 and will [...]
CX 2018: Landmark EVRA trial provides first Level 1 evidence for early endovenous ablation
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of [...]